Er:YAG laser-PDT combined with anti- programmed cell death protein-1 for refractory oral potential malignant disorders following oral squamous cell carcinoma surgery.
1/5 보강
Oral potential malignant disorders (OPMDs) have a high risk of malignant transformation and recurrence.
APA
Rao Q, Feng C, et al. (2026). Er:YAG laser-PDT combined with anti- programmed cell death protein-1 for refractory oral potential malignant disorders following oral squamous cell carcinoma surgery.. Photodiagnosis and photodynamic therapy, 58, 105383. https://doi.org/10.1016/j.pdpdt.2026.105383
MLA
Rao Q, et al.. "Er:YAG laser-PDT combined with anti- programmed cell death protein-1 for refractory oral potential malignant disorders following oral squamous cell carcinoma surgery.." Photodiagnosis and photodynamic therapy, vol. 58, 2026, pp. 105383.
PMID
41654061
Abstract
Oral potential malignant disorders (OPMDs) have a high risk of malignant transformation and recurrence. This case reports describes a novel therapeutic strategy of Er:YAG laser-assisted photodynamic therapy (Er:YAG-PDT) combined with anti-programmed death protein-1 (anti-PD-1) immunotherapy for a patient with refractory OPMDs in the right lower gingiva following oral squamous cell carcinoma (OSCC) surgery on the contralateral side. Initial PDT alone showed limited efficacy, but after integrating Er:YAG laser pretreatment, the patient achieved significant lesion regression, with a complete final clearance. The 6-month follow-up showed good local lesion control in the patient peripheral blood analysis revealed elevated natural killer (NK) cell level and reduced regulatory T (Treg) cell percentage, suggesting activated adaptive immunity, while similar CD8⁺ T cell levels indicated maintained immune homeostasis. This case report highlights the potential of combined Er:YAG-PDT and anti-PD-1 therapy for OPMDs, while emphasizing the need for optimized monitoring and multi-modal strategies to prevent recurrence in high-risk patients.
🏷️ 키워드 / MeSH
- Humans
- Photochemotherapy
- Lasers
- Solid-State
- Photosensitizing Agents
- Mouth Neoplasms
- Programmed Cell Death 1 Receptor
- Male
- Carcinoma
- Squamous Cell
- Combined Modality Therapy
- Middle Aged
- Neoplasm Recurrence
- Local
- Anti- Programmed cell death protein-1(Anti- PD-1)
- Er:YAG laser
- Immunotherapy
- Oral potential malignant disorders (OPMDs)
- Oral squamous cell carcinoma (OSCC)
- Photodynamic therapy (PDT)